Roth Capital Reduces Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Equities researchers at Roth Capital cut their Q2 2025 earnings per share estimates for shares of Zimmer Biomet in a research note issued to investors on Tuesday, May 6th. Roth Capital analyst J. Wittes now expects that the medical equipment provider will post earnings of $1.79 per share for the quarter, down from their previous estimate of $2.04. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Roth Capital also issued estimates for Zimmer Biomet's Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.29 EPS, FY2025 earnings at $7.90 EPS, Q1 2026 earnings at $1.81 EPS, Q2 2026 earnings at $2.13 EPS, Q3 2026 earnings at $1.93 EPS, Q4 2026 earnings at $2.47 EPS and FY2026 earnings at $8.34 EPS.

A number of other equities analysts have also commented on the company. Raymond James lowered their price objective on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. JMP Securities cut their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, May 6th. Finally, Barclays dropped their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $113.45.

Zimmer Biomet Stock Performance

NYSE ZBH traded down $0.77 during trading on Thursday, reaching $97.45. The company's stock had a trading volume of 1,100,970 shares, compared to its average volume of 2,101,093. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $19.28 billion, a price-to-earnings ratio of 21.90, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The firm has a 50 day moving average price of $104.30 and a 200 day moving average price of $106.10. Zimmer Biomet has a 12 month low of $89.92 and a 12 month high of $122.17.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet's quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the company posted $1.94 earnings per share.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.99%. Zimmer Biomet's payout ratio is currently 21.24%.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.39% of the company's stock.

Institutional Trading of Zimmer Biomet

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider's stock worth $2,609,130,000 after buying an additional 166,763 shares in the last quarter. Dodge & Cox increased its position in shares of Zimmer Biomet by 12.0% during the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after acquiring an additional 2,044,645 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Zimmer Biomet by 1.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock valued at $1,559,147,000 after acquiring an additional 176,337 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after purchasing an additional 218,688 shares during the period. Finally, Franklin Resources Inc. grew its stake in Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.